Tuberculin Skin Testing and Managing a Positive Tuberculin Reactor

  • Nelson M. Gantz


Tuberculosis continues to be a serious problem in the United States. It is imported regularly from the Third World, and it is often seen in the elderly.1 There is also an increase in tuberculosis infections caused by Mycobacterium tuberculosis and M. avium-intracellulare complex in patients with diagnosed AIDS.


Tuberculin Skin Test Active Tuberculosis Tuberculosis Infection Purify Protein Derivative Positive Skin Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stead WW, Lofgren JP, Warren E, et al: Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N Engl J Med 1985; 312: 1483–1487.PubMedCrossRefGoogle Scholar
  2. 2.
    American Thoracic Society: The tuberculin skin test. Am Rev Respir Dis 1981; 124: 356–363.Google Scholar
  3. 3.
    Snider DE Jr: The tuberculin skin test. Am Rev Respir Dis 1982; 125: 108–118.PubMedGoogle Scholar
  4. 4.
    Nash DR, Douglass JE: Anergy in active pulmonary tuberculosis: A comparison between positive and negative reactors and an evaluation of 5 TU and 250 TU skin test doses. Chest 1980; 77: 32–37.PubMedCrossRefGoogle Scholar
  5. 5.
    Sokal JE: Measurement of delayed skin-test responses. N Engl J Med 1975; 293: 50 1502.Google Scholar
  6. 6.
    Thompson NJ, Glassroth, JL, Snider DE Jr, et al: The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979; 119: 507–597.Google Scholar
  7. 7.
    Simon JA, McVicker SJ, Ferrell CR, et al: Two-step tuberculin testing in a veterans domiciliary population. South Med J 1983; 76: 866–869.PubMedCrossRefGoogle Scholar
  8. 8.
    Snider DE, Cauthen GM: Tuberculin skin testing of hospital employees: Infection, “boosting,” and two-step testing. Am J Infect Control 1984; 12: 305–311.PubMedCrossRefGoogle Scholar
  9. 9.
    Kallay MC, Bell KM, Montalbano B: False positive reactions to Aplisol (Parke-Davis) with serial PPD skin testing (abstract). Am Rev Respir Dis 1987; 135 (Suppl): A45.Google Scholar
  10. 10.
    Johnston WW, Saltzman HA, Bufkin JH, et al: The tuberculin test and the diagnosis of clinical tuberculosis. Am Rev Respir Dis 1960; 81: 189–195.PubMedGoogle Scholar
  11. 11.
    Snider DE Jr. Bacille Calmette-Guerin vaccination and tuberculin skin test. JAMA 1985; 253: 3438–3439.PubMedCrossRefGoogle Scholar
  12. 12.
    Kent DC, Reid D, Sokolowski. JW, et al: Tuberculin conversion. The iceberg of tuberculosis pathogenesis. Arch Environ Health 1967; 14: 580–584.PubMedCrossRefGoogle Scholar
  13. 13.
    Moulding T: Chemoprophylaxis of tuberculosis: When is the benefit worth the risk and cost ? Ann Intern Med 1971; 74: 761–770.PubMedCrossRefGoogle Scholar
  14. 14.
    American Thoracic Society, American Lung Association, and Centers for Disease Control: Preventive therapy for tuberculosis infection. Am Rev Respir Dis 1974; 110: 371–374.Google Scholar
  15. 15.
    Sahn SA, Lakshminarayan S: Tuberculosis after corticosteroid therapy. Br J Dis Chest 1976; 70: 195–205.PubMedCrossRefGoogle Scholar
  16. 16.
    Kaplan MH, Armstrong D, Rosen P: Tuberculosis complicating neoplastic disease: A review of 201 cases. Cancer 1974; 33: 850–858.PubMedCrossRefGoogle Scholar
  17. 17.
    Befeler B, Baum GL: Active pulmonary tuberculosis after upper gastrointestinal surgery. Am Rev Respir Dis 1967; 96: 977–980.PubMedGoogle Scholar
  18. 18.
    Rose DN, Silver AL, Schechter CB: Tuberculosis chemoprophylaxis for diabetics: Are the benefits of isoniazid worth the risk? Mt Sinai J Med 1985; 52: 253–258.PubMedGoogle Scholar
  19. 19.
    Curry FJ: Prophylactic effect of isoniazid in young tuberculin reactors. N Engl J Med 1967; 277: 562–567.PubMedCrossRefGoogle Scholar
  20. 20.
    Hsu KHK: Isoniazid in the prevention and treatment of tuberculosis. A 20-year study of the effectiveness in children. JAMA 1974; 229: 528–533.PubMedCrossRefGoogle Scholar
  21. 21.
    Comstock GW, Edwards PQ: The competing risks of tuberculosis and hepatitis for adult tuberculin reactors. Am Rev Respir Dis 1975; 111: 573–577.PubMedGoogle Scholar
  22. 22.
    Taylor WC, Aronson MD, Delbanco TL: Should young adults with a positive tuberculin test take isoniazid? Ann Intern Med 1981; 94: 808–813.PubMedCrossRefGoogle Scholar
  23. 23.
    Comstock GW: Evaluating isoniazid preventive therapy: The need for more data. Ann Intern Med 1981; 94: 817–819.PubMedCrossRefGoogle Scholar
  24. 24.
    Rose DN, Schechter CB, Silver AL: The age threshold for isoniazid chemoprophylaxis. JAMA 1986; 256: 2709–2713.PubMedCrossRefGoogle Scholar
  25. 25.
    Stead WW, To T, Harrison RW, et al: Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann Intern Med 1987; 107: 843–845.PubMedCrossRefGoogle Scholar
  26. 26.
    Snider DE, Caras, GJ, Koplan JP: Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA 1986; 255: 1579–1583.PubMedCrossRefGoogle Scholar
  27. 27.
    Thompson NJ: Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of followup in the IUAT trial. Bull WHO 1982; 60: 555–564.Google Scholar
  28. 28.
    Centers for Disease Control: Drug resistance among Indochinese refugees with tuberculosis. Morbid Mortal Week Rep 1981; 30: 273–274.Google Scholar
  29. 29.
    Mitchell JR, Zimmerman HJ, Ishak KG, et al: Isoniazid liver injury: Clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 1976; 84: 181–192.PubMedCrossRefGoogle Scholar
  30. 30.
    Black M, Mitchell JR, Zimmerman Hi, et al: Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69: 289–302.PubMedGoogle Scholar

Additional Readings

  1. Snider DE Jr: Decision analysis for isoniazid preventive therapy: Take it or leave it ? Am Rev Respir Dis 1988; 137: 2–3.PubMedCrossRefGoogle Scholar
  2. Snider DE, Farer LS: Preventive therapy for tuberculosis infection: An intervention in need of improvement. Am Rev Respir Dis 1984; 130: 355–356.PubMedGoogle Scholar
  3. Tsevat J, Taylor WC, Wong JB, et al: Isoniazid for the tuberculin reactor: Take it or leave it. Am Rev Respir Dis 1988; 137: 215–220.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Nelson M. Gantz

There are no affiliations available

Personalised recommendations